(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
11 April 2013 (11.04.2013)

WIPO | PCT

(10) International Publication Number
WO 2013/052006 A1

(51) International Patent Classification:
A61K 31/711 (2006.01) *A61K 31/7088* (2006.01)
A61K 31/713 (2006.01) *A61P 31/20* (2006.01)
A61P 35/00 (2006.01)

(21) International Application Number:
PCT/SG2011/000351

(22) International Filing Date:
7 October 2011 (07.10.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
201007366-6 7 October 2011 (07.10.2011) SG

(71) Applicant *(for all designated States except US)*: **AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (A*STAR)** [SG/SG]; 1 Fusionopolis Way, #20-10 Connexis, Singapore 138632 (SG).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **REN, Ee Chee** [MY/SG]; Singapore Immunology Network (SIgN), 8A Biomedical Grove, Immunos Building, Level 4, Singapore 138648 (SG). **KO, Hui Ling** [SG/SG]; Singapore Immunology Network (SIgN), 8A Biomedical Grove, Immunos Building, Level 4, Singapore 138648 (SG).

(74) Agent: **KHOO, Chong Yee**; Cantab LLP, VBox 881846, Singapore 919191 (SG).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

(54) Title: PARP-1 INHIBITORS

FIGURE 1A



(57) Abstract: We describe a nucleic acid comprising the sequence RNNWCAAA, in which R is independently G or A, N is independently T, C, G or A and W is independently T or A, suitable for the treatment or prevention of hepatitis B or cancer. N at position 3 may be C, A or T, preferably A or T, more preferably T; N at position 2 may be C; W at position 4 may be T; and R at position 1 may be A. The nucleic acid may have the sequence ACATCAAA or ACTTCAAA.

WO 2013/052006 A1